{"id":49912,"date":"2022-10-21T15:02:49","date_gmt":"2022-10-21T13:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/"},"modified":"2022-10-21T15:02:49","modified_gmt":"2022-10-21T13:02:49","slug":"asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/","title":{"rendered":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022"},"content":{"rendered":"
\n

\nShows potential for CD8+ T cell targeted immunotherapy for chronic viral infections<\/b><\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio),<\/a> a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, its CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections, at the American Association for the Study of Liver Disease (AASLD) 2022 Annual Meeting, being held in Washington, DC, on November 4-8, 2022. The preclinical data indicates that selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a model of hepatitis B virus (HBV) and supports the development of AB359 as a potentially more tolerable and more active IL\u20112-based therapy for the treatment of chronic HBV.\n<\/p>\n

<\/a><\/p>\n

\nDetails of the poster presentation are as follows:\n<\/p>\n

\nTitle:<\/b> Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a hepatitis B virus (HBV) model
\n
Session Date and Time: <\/b>November 4, 2022, 12:00-1:00 p.m. ET
\n
Location: <\/b>Poster Hall
<\/b>Abstract Number: <\/b>1198\n<\/p>\n

\nAbout Asher Bio<\/b>\n<\/p>\n

\nAsher Bio <\/a>is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders. We utilize our proprietary cis-targeting platform<\/a> to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com<\/b><\/a> and follow us on Twitter @AsherBio<\/b><\/a> and on LinkedIn<\/b><\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact
\n
<\/b>Kathryn Morris, The Yates Network
\n
914-204-6412
\n
kathryn@theyatesnetwork.com<\/a>\n<\/p>\n

\nInvestor Contact
\n
<\/b>Hannah Deresiewicz, Stern Investor Relations, Inc.
\n
212-362-1200
\n
hannah.deresiewicz@sternir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49912","6":"format-standard","7":"category-industry"},"yoast_head":"\nAsher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-21T13:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022\",\"datePublished\":\"2022-10-21T13:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/\"},\"wordCount\":369,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005054\\\/en\\\/1607376\\\/21\\\/AsherBio-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/\",\"name\":\"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005054\\\/en\\\/1607376\\\/21\\\/AsherBio-logo.jpg\",\"datePublished\":\"2022-10-21T13:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005054\\\/en\\\/1607376\\\/21\\\/AsherBio-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005054\\\/en\\\/1607376\\\/21\\\/AsherBio-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/","og_locale":"en_US","og_type":"article","og_title":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend","og_description":"Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-21T13:02:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022","datePublished":"2022-10-21T13:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/"},"wordCount":369,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/","url":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/","name":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg","datePublished":"2022-10-21T13:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221021005054\/en\/1607376\/21\/AsherBio-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/asher-bio-to-present-first-preclinical-data-for-ab359-its-cd8-targeted-il-2-immunotherapy-for-hepatitis-b-at-aasld-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49912"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49912\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}